Pennsylvania


 
Support Maps
MAPS’ mission is to treat conditions for which conventional medicines provide limited relief, such as PTSD & anxiety associated with life-threatening illnesses, by developing psychedelics & marijuana into prescription medicines.
Federal Agencies Say Yes to Psychedelic Studies,
No to Medical Marijuana: MAPS E-Mail Newsletter
October 24, 2011

Dear [xxxx],
Welcome to the October 2011 edition of the MAPS E-mail Newsletter.I have a lot to share with you this month, from original studies and research results to upcoming events and some fascinating new documentaries about psychedelic science and medicine. Read on to learn what’s new in the MAPS Storeand discover how MAPS supporters are making the psychedelic renaissance possible.

Donate Make a Contribution

There’s good news and bad news, but even the bad news these days is opening up doors rather than closing them.

In August, the U.S. Drug Enforcement Administration upheld the federal monopoly on marijuana for research by denying University of Massachusetts-Amherst professor Lyle Craker, Ph.D., a license to start his own medical marijuana facility.

On September 16, we saw why the federal monopoly needs to end when the Department of Health and Human Services rejected our planned, FDA-reviewed study of marijuana for 50 veterans with posttraumatic stress disorder (PTSD) and refused to sell us the marijuana we require for the study.

In response, we’re taking the DEA to federal court and doing everything we can to remind the public what can happen when science is silenced by politics: studies don’t get started, medicines don’t get made, and patients don’t get treated.

Public support is building fast for psychedelic and medical marijuana research. The Washington Post, The Guardian, Salon, The Huffington Post, and other major media have reported on our international MDMA-assisted psychotherapy research program and the government’s medical marijuana research blockade.

In just six weeks, you’ll have a chance to join the leaders in psychedelic and medical marijuana research, therapy, and activism at Cartographie Psychedelica, our 25th anniversary conference and celebration in the San Francisco Bay Area. There has never before been a better chance to connect with the multidisciplinary psychedelic research community and to discover what’s in store for the next 25 years.

Opportunities are everywhere. Please join me in doing everything we can to make our shared dreams a reality: donate today.

 
In gratitude,

Brad Burge, M.A.
MAPS Director of Communications

MDMA Research News:

  1. US Veterans MDMA/PTSD Study Continues Treating Subjects
  2. New MDMA/PTSD Training Videos Under Development
  3. Mithoefers to Lead MDMA-Assisted Psychotherapy Workshop at 25th Anniversary Conference
  4. DEA Approves US MDMA/PTSD Relapse Study Protocol
  5. Israeli MDMA/PTSD Study Initiated
  6. Swiss MDMA/PTSD Study Final Report Submitted to SwissMedic
  7. Health Canada Schedules Follow-Up Pharmacy Inspection for MDMA/PTSD Study

More Research News:

  1. NIDA Rejects Marijuana Protocol, Blocking FDA-Approved Research for Vets with PTSD
  2. Last Two-Month Follow-Up Completed in Swiss Study of LSD-Assisted Psychotherapy for End-of-Life Anxiety
  3. Canadian Study Explores Ayahuasca-Assisted Therapy for Addiction and Dependence
  4. MAPS Hungary Publishes Report on European Ayahuasca Research Symposium
  5. Observational Study of Ibogaine Treatment for Addiction Enrolls Final Subject
  6. Clinical Team Prepares Protocol for New Study of Ibogaine Treatment for Addiction in New Zealand
  7. Autism Protocol Development: MAPS Releases Request for Proposals (RFP)

Events:

  1. Cartographie Psychedelica: December 8-12, Oakland, CA
  2. International Drug Policy Reform Conference: November 2-5, Los Angeles, CA
  3. Spirituality & Psychology Conference: February 17-19, 2012, Atherton, CA

Media:

  1. Washington Post Makes Federal Marijuana Research Blockade National News
  2. Public Support Builds for MAPS’ International Psychedelic Research
  3. Mind Body Health & Politics Radio Show Hosts Psychedelic Medicine Series
  4. DMT: The Spirit Molecule Now Available on Video
  5. Dirty Pictures Documentary Looks at the Genesis of MDMA
  6. Yarindin Documentary Explores Trauma, Combat, and Psychedelic Healing

Fundraising News:

  1. MAPS Celebrates Recent Fundraising Successes

New in the MAPS Store:

  1. The Psychedelic Journey of Marlene Dobkin de Rios: 45 Years with Shamans, Ayahuasqueros, and Ethnobotanists
  2. The Psilocybin Solution: The Role of Sacred Mushrooms in the Quest for Meaning

More News:

  1. Donate an Item to MAPS’ 25th Anniversary Adventure Auction
  2. International Ayahuasca Researchers to Meet at Cartographie Psychedelica
  3. A Deck of Medicine: Stormrider Calling Cards by Requa Greer Tolbert
  4. MAPS Welcomes New Staff to the Office

MDMA Research News1. US Veterans MDMA/PTSD Study Continues Treating SubjectsAs of October 21, 2011, our ongoing Phase 2 study of MDMA-assisted psychotherapy for U.S. veterans with chronic, treatment-resistant PTSD has enrolled five out of 16 subjects. Three subjects have started the long-term follow-up portion of the study, and two are still in treatment. Two additional veterans have passed in-person screening, involving thorough assessments of PTSD severity and medical eligibility, with their treatment sessions soon to be scheduled. One subject has chosen to discontinue treatment after just one experimental MDMA-assisted psychotherapy session, reporting being cured and needing no further sessions.

2. New MDMA/PTSD Training Videos Under Development

Two essential parts of conducting methodologically rigorous and state-of-the-art MDMA-assisted psychotherapy research are standardizing the method of MDMA-assisted psychotherapy itself and the method by which data is collected about subjects’ PTSD symptoms. We have standardized our treatment in our MDMA-assisted psychotherapy treatment manual and related adherence criteria. Having a consistent, reliable way to measure PTSD symptoms at baseline and over time during and after treatment is also essential.

MAPS has recently completed the development of a training manual for independent raters who conduct the Clinician-Administered PTSD Scale (CAPS) interviews in our international series of Phase 2 MDMA/PTSD pilot studies. The CAPS is the primary measure used by clinicians and therapists worldwide for evaluating the severity of PTSD symptoms, and is the principle measure we use to assess the effectiveness of our treatment method.

The CAPS training manual will be supplemented by video tutorials of CAPS interviews, drawn from actual recordings of interviews with subjects enrolled in our ongoing study of MDMA-assisted psychotherapy for PTSD in veterans of war. By building on the training materials provided by the U.S. Veterans Administration, creating Hebrew and Arabic versions of the CAPS through rigorous double back translation methods, and providing a uniform set of training tools for independent raters, we will be able to standardize how the CAPS is administered across study sites. This is a necessary step before moving on to the larger Phase 3 studies required for federal approval of MDMA-assisted psychotherapy as a legal treatment for PTSD.

3. Mithoefers to Lead MDMA-Assisted Psychotherapy Workshop at 25th Anniversary Conference

Lead study investigators and co-therapists Michael Mithoefer, M.D., and Annie Mithoefer, B.S.N., will conduct an all-day pre-conference workshop on Friday, December 9, as part of our 25th anniversary Cartographie Psychedelica conference and celebration. “The Principles of Psychedelic Therapy: Lessons from Clinical MDMA Research” will examine past and current research into psychedelic therapy, specifically focusing on recent findings from our ongoing MDMA-assisted psychotherapy research program.

4. DEA Approves US MDMA/PTSD Relapse Study Protocol

In early November, the official study initiation will take place for our new “relapse study” of MDMA-assisted psychotherapy for PTSD. Previously, on September 14, the Drug Enforcement Administration (DEA) notified MAPS that it had approved the Schedule 1 licenses required to transport, store, and administer the MDMA for the study. The FDA cleared the protocol on May 24 and an Institutional Review Board on June 9. With all necessary clearances, we will begin enrolling subjects in November.

This study, which will take place in Charleston, SC, is limited to up to three subjects whose PTSD symptoms returned years after participating in our flagship Phase 2 clinical trial of MDMA-assisted psychotherapy for PTSD. It will attempt to determine whether a single additional open-label MDMA-assisted psychotherapy session along with several non-drug psychotherapy sessions can be effective for once again enabling these subjects to be free of a diagnosis of PTSD.

5. Israeli MDMA/PTSD Study Initiated

On October 12, 2011, the new Independent Rater in MAPS’ Israeli study of MDMA-assisted psychotherapy for PTSD began working on the training videos that we have created to standardize how the Clinician-Administered PTSD Scale is administered across all of our treatment sites. This CAPS training is the last major element to complete before we can start enrolling and treating subjects. The official study initiation took place on July 24, when representatives from Antaea Medical Services, Ltd., the clinical research organization assisting MAPS with managing our Middle East studies, visited the site to finalize documents and provide training to the study staff. The study has all necessary clearances from Israeli regulatory bodies, including the Israeli Ministry of Health and an independent Ethics Committee. We have also submitted the protocol to the U.S. FDA, which is required because we are conducting the study under a U.S. Investigational New Drug application. The Israeli Defense Forces are already prepared to begin referring Israelis with chronic, treatment-resistant PTSD once we are ready to enroll subjects, probably before 2012.

6. Swiss MDMA/PTSD Study Final Report Submitted to SwissMedic

On October 14, 2011, MAPS’ clinical research team submitted the final clinical study report for our recently completed Phase 2 Swiss study of MDMA-assisted psychotherapy for people with chronic, treatment-resistant PTSD to SwissMedic, the Swiss equivalent of the U.S. FDA. SwissMedic confirmed that the report had been received on October 18. The report, authored by MAPS Lead Clinical Research Associate Berra Yazar-Klosinski, Ph.D., and MAPS Research and Information Specialist Ilsa Jerome, Ph.D., is required under International Council on Harmonization/Good Clinical Practice (ICH/GCP) and FDA regulations. The report contains information about the study protocol, information about the conduct of the study, and all study data in both raw and analyzed formats. The study team is now preparing the results for publication in a peer-reviewed academic journal.

A statistical analysis of the results reveals clinically significant decreases in scores on the Clinician-Administered PTSD Scale (CAPS), with an average reduction of 15.6 points. Due to the small number of subjects in this small pilot study, however, these decreases did not reach statistical significance. We did, however, observe trends toward statistical significance in both the CAPS and the Posttraumatic Diagnostic Scale (PDS), the two measures used to evaluate symptom severity in study subjects.

7. Health Canada Schedules Follow-Up Pharmacy Inspection for MDMA/PTSD Study

On October 18, 2011, Health Canada conducted a follow-up inspection of the pharmacy for our planned Phase 2 Canadian study of MDMA-assisted psychotherapy for PTSD. We expect that Health Canada will report on the results of this inspection within four to six weeks. Frustratingly, even though we followed Health Canada’s exact written requirements, the requirements have now changed and additional security measures may be needed. This will delay the start of the study for several additional months. The pharmacy inspection is required under Canadian regulations to ensure that the facility used to store and label the MDMA to be used in the study is adequately secure, and that the proper accountability procedures are in place. Once we obtain clearance from Health Canada we will be able to import the MDMA for the study into Canada from Switzerland.

The lead investigator for this study, Ingrid Pacey, M.D., will speak on the MDMA-Assisted Psychotherapy for PTSD Research Panel at our 25th anniversary conference this December.

More Research News

8. NIDA Rejects Marijuana Protocol, Blocking FDA-Approved Research for Vets with PTSD

On September 16, 2011, after a delay of four and a half months, the US Department of Health and Human Services informed MAPS that the five reviewers from the National Institute on Drug Abuse/Public Health Service had unanimously rejected our planned study of marijuana for veterans with PTSD as currently designed. According to MAPS Executive Director Rick Doblin, Ph.D., the reviewers offered contradictory critiques, misunderstood key protocol design elements, requested expensive and tangential additions to the protocol, and made unfounded assumptions about the study design, revealing their focus on basic science research and lack of familiarity with drug development research. The reviewers also treated the submission as if MAPS were requesting a government grant for the study rather than using private funds. Even if NIDA does eventually agree to sell MAPS the marijuana, getting to that point will take extensive, time-consuming, and costly negotiations—while veterans continue to suffer.

For a concise summary of the HHS review, see the September 16 HHS cover letter. For MAPS’ detailed, point-by-point response to the HHS review, see the annotated reviewer comments.

Download MAPS’ official press release announcing the HHS rejection.

9. Last Two-Month Follow-Up Completed in Swiss Study of LSD-Assisted Psychotherapy for End-of-Life Anxiety

By October 21, 2011, five out of 12 subjects have completed the long-term follow-up portion of our Swiss study of LSD-assisted psychotherapy for anxiety associated with advanced-stage illness. These long-term follow-ups take place at least 10 months following subjects’ final treatment sessions. The last two-month follow-up visit was completed on July 26, 2011. This concludes the data collection portion of the first clinical LSD study in over 35 years. The results from the treatment period of the study are now being prepared for publication in a peer-reviewed scientific journal. The clinical team is now collecting long-term follow-up data in the form of additional interviews and psychiatric measures from subjects who have completed treatment, 10 or more months after their final treatment session. Five out of 12 subjects have now completed the long-term follow-up portion of the study. Once this data has been collected, the clinical team will prepare the final report for submission to SwissMedic and the U.S. FDA, and will submit the results for publication in a peer-reviewed scientific journal.

Principal Investigator Peter Gasser, M.D., will be giving a lecture and answering questions about LSD-assisted psychotherapy for end-of-life anxiety at our 25th anniversary conference this December.

10. Canadian Study Explores Ayahuasca-Assisted Therapy for Addiction and Dependence

On September 23, 2011, the final treatment session (consisting of a five-day therapeutic retreat) took place in MAPS Canada’s observational study of ayahuasca-assisted therapy for individuals suffering from addiction and dependence. The research team has now recruited and is following up with 15 study subjects that have been treated. This study is taking place in British Columbia, and is overseen by MAPS Canada Board Member Philippe Lucas, M.A., with Principal Investigator Gerald Thomas, Ph.D., Rielle Capler, M.H.A., and Kenneth Tupper, Ph.D. Combining Western psychotherapeutic techniques with South American shamanic (Vegetalista) healing practices, this study is gathering preliminary evidence about the safety and effectiveness of ayahuasca-assisted therapy. Treatment consists of participation in a five-day retreat (facilitated by Gabor Maté, M.D.) including ayahuasca-assisted therapy, which may help reduce problematic substance use as well as addictions, compulsive behavior, and self-harming thought patterns. The study is being conducted in cooperation with a British Columbia First Nations band.

Philippe Lucas, M.A., will speak on ayahuasca research for addiction, and Lucas and Kenneth Tupper, Ph.D., will help lead the all-day “Ayahuasca Healing: Medical, Legal, and Cultural Considerations” workshop at our 25th anniversary conference this December.

11. MAPS Hungary Publishes Report on European Ayahuasca Research Symposium

On October 15, 2011, the Multidisciplinary Association for Psychedelic Studies, Hungary (MAPS Hungary) completed a report on the European Ayahuasca Research Symposium (EARS), a half-day seminar co-sponsored by Stichting OPEN and MAPS which took place in April 2011 at the University of Amsterdam. Over 300 people were in attendance. The Symposium brought together researchers from across Europe who over the last few years have been studying ayahuasca and DMT within the disciplines of anthropology, neuroscience, psychology, and religious studies. The next morning, other European ayahuasca scholars joined presenters from the seminar for a closed-door researcher workgroup intended to stimulate future ayahuasca research and possible collaborations in Europe. The workgroup succeeded in building a shared knowledge base of ongoing and planned ayahuasca research, in facilitating discussions on methodology and obtaining institutional approvals for research, and in developing personal and professional contacts among the few ayahuasca researchers currently based in Europe. The short report shares some of the highlights of the workgroup.

12. Observational Study of Ibogaine Treatment for Addiction Enrolls Final Subject

The 30th and final subject was enrolled in our ongoing observational study of ibogaine treatment for addiction on August 29, 2011. This final subject has completed treatment at an independent ibogaine clinic in Mexico and will be evaluated for addiction and quality of life for 12 months. As of October 20, 2011, 28 subjects have completed their three-month follow-up interviews, and 20 have completed the six-month follow-up interviews. Given the increasing numbers of people around the world seeking ibogaine treatment for drug addiction, this study aims to gather evidence about the safety and effectiveness of the treatment and to compare different approaches to that treatment.

Thomas Kingsley Brown, Ph.D., the lead investigator for the study, will be speaking about the goals and progress of MAPS’ ibogaine research program on Saturday, December 10 at Cartographie Psychedelica, our 25th anniversary conference in Oakland, CA.

13. Clinical Team Prepares Protocol for New Study of Ibogaine Treatment for Addiction in New Zealand

On October 17, 2011, the lead investigators for MAPS’ ibogaine research program held a conference call to discuss the next steps for our new observational study of ibogaine treatment for addiction in New Zealand. Thomas Kingsley Brown, Ph.D., who leads our U.S.-based study of independent ibogaine clinics in Mexico, and Geoff Noller, Ph.D., who will lead the new study, shared perspectives and lessons from ibogaine therapy research in order to guide the development of the new study protocol. The new study will take place at an independent ibogaine clinic in New Zealand, and will examine the safety and long-term effectiveness of ibogaine treatment for addiction severity and quality of life in 20 to 30 patients. The clinical team will submit the protocol and other documents to the Ethics Committee by the end of October.

Since this will be an observational study (as opposed to clinical) the protocol does not need to pass through an additional review process, meaning that we can begin enrolling subjects as soon as the study clears the Ethics Committee. Data from this study and our ongoing study of Mexican ibogaine treatment centers may be used to make a case for a possible future clinical study (see our original ibogaine Request for Proposals).

14. Autism Protocol Development: MAPS Releases Request for Proposals (RFP)

MAPS is offering a grant of $10,000 for protocol development expenses for a pilot study of MDMA for the treatment of high-functioning autism or Asperger’s syndrome. We have prepared a Request for Proposals (RFP) for U.S.-based researchers. One of the factors that we’ll look for in selecting a research team is whether they would also have a chance of obtaining funds for research from other grant agencies (autism research is currently a well-funded field). At present, we do not have the funds for the study itself but we do have funds for protocol development. Once we have a completed protocol, we can develop a budget and a fundraising plan. MAPS itself would be in a much better position to raise funds for a study with a completed protocol from a qualified research team.

To facilitate the protocol development process, MAPS has collected numerous anecdotal reports from individuals with Autism Spectrum Disorders who have used MDMA or Ecstasy. Many of these accounts are from people who considered MDMA to be helpful. If you or someone you know has heard of MDMA having either positive or negative effects on symptoms of Autism Spectrum Disorders or Asperger’s syndrome, please contact MAPS Lead Clinical Research Associate Berra Yazar-Klosinski, Ph.D., at berra@maps.org.

Events

15. Cartographie Psychedelica: December 8-12, Oakland, CA

16. International Drug Policy Reform Conference: November 2-5, Los Angeles, CA

17. Spirituality & Psychology Conference: February 17-19, 2012, Atherton, CA

Media

18. Washington Post Makes Federal Marijuana Research Blockade National News

On October 1, 2011, the Washington Post continued the trend of positive media coverage with an exposé about the federal government’s refusal to sell us marijuana for the planned study (“Marijuana study of traumatized vets stuck in regulatory limbo”, October 1, 2011). See MAPS’ official press release for more about the federal obstruction of medical marijuana research, and learn why MAPS is taking the DEA to federal court.

The exposé was followed two weeks later by a persuasive Washington Post op-ed condemning the federal government’s ongoing refusal to allow legitimate, necessary medical marijuana research from moving forward (“Marijuana may help PTSD. Why won’t the government find out for sure?” October 14, 2011).

Steve Fox of the Marijuana Policy Project writes: “It is time for government officials to take this nation’s veterans off the medical marijuana battlefield. NIDA should grant the researchers’ request to purchase marijuana and allow the FDA-approved study of veterans to move forward. These brave men and women don’t have decades to wait for relief.”

19. Public Support Builds for MAPS’ International Psychedelic Research

On September 30, 2011, The Guardian reported on a possible new MAPS-sponsored study of MDMA-assisted psychotherapy for PTSD to take place in the UK (“Ecstasy trial planned to test benefits for trauma victims”, September 30, 2011). MAPS, together with psychopharmacologist Dr. David Nutt and psychiatrist Dr. Ben Sessa, are considering submitting a grant proposal to a major UK foundation for the study. If it receives funding and regulatory approval, the study would be the first of its kind in the UK. The article concludes with Dr. Nutt’s observation that more cautious UK media such as The Daily Mail would not welcome the news, a recent positive article in that same publication clearly shows that times are changing. As The Guardian article points out, MAPS’ research on MDMA-assisted psychotherapy for PTSD “has caused some in the scientific community to think what was until recently unthinkable.”

Additional coverage of MAPS’ possible UK study of MDMA-assisted psychotherapy for PTSD also appeared in The Herald Sun, the Sydney Morning Herald, the Hindustan Times, and The Times of India.

A long and in-depth article on Salon.com also shed light on the wide-open field of medical psychedelic research, focusing primarily on recent and ongoing studies at NYU and Johns Hopkins. You may also remember that last year, the influential medical journal The Lancet Oncology noted that the growing support for psychedelic and (in public opinion if not government policy) medical cannabis research is part of a larger pattern involving “the increased willingness of researchers and regulatory bodies to look beyond stigma, and take a more rational approach to the controlled medical use of compounds that are more often linked with the war on drugs.”

For more snapshots of how MAPS is helping change how the world sees psychedelics and medical marijuana, visit MAPS in the Media.

20. Mind Body Health & Politics Radio Show Hosts Psychedelic Medicine Series

“Mind Body Health & Politics” with Dr. Richard Miller is hosting a series on Psychedelic Medicine, featuring personal interviews with scientists and thinkers in psychedelic and medical marijuana research. “Mind Body Health & Politics” airs the first and third Tuesday of the month at 9 AM on National Public Radio affiliate KZYX FM (Mendocino County Public Radio). You can also listen live online at mindbodyhealthpolitics.org.

Past Shows:

  • Psychedelic Medicine I: Ethnobotany with Dennis McKenna
    Dennis McKenna, Ph.D., has conducted research in ethnopharmacology for over 30 years. He currently teaches at the Center for Spirituality and Healing at the University of Minnesota. Listen to Dr. Miller and Dr. McKenna discuss enthnobotany and pharmacology of ayahuasca and oo-koo-he. Broadcasted September 20, 2011 (mp3).
  • Psychedelic Medicine II: The Historic MDMA study
    Dr. Miller and MAPS researchers Michael Mithoefer, M.D., and Ann Mithoefer, B.S.N., discuss their FDA-approved clinical trials of 3,4-methylenedioxymethamphetamine (MDMA) as a therapeutic tool to assist psychotherapy for the treatment of posttraumatic stress disorder (PTSD). Preliminary studies have shown that MDMA in conjunction with psychotherapy can help people overcome PTSD, and possibly other disorders as well. MDMA has “empathogenic” effects, meaning that it increases feelings of trust and compassion towards others. Broadcasted October 4, 2011 (mp3).
  • Psychedelic Medicine III: The Psychedelic Explorer’s Guide
    Jim Fadiman, Ph.D. discusses his new book The Psychedelic Explorer’s Guide: Safe, Therapeutic and Sacred Journeys (available in the MAPS Store). Dr. Fadiman is one of the foremost pioneers of scientific research of the potential of psychedelic substances for therapy, self-discovery, spiritual quests and creative problem solving, has written an invaluable guide for safe and productive sessions. Broadcasted October 18th, 2011 (mp3).

Upcoming Shows:

  • November 1: Mark Blumenthal , Ph.D., founder and executive director of the American Botanical Council.
  • November 15: Dave Nichols, Ph.D., pharmacologist, medicinal chemist, founding president of the Heffter Research Institute, and one of the world’s leading experts on psychedelics.
  • November 29: Charles Grob, M.D., psychiatrist, psilocybin researcher, and conductor of the first government-approved study of MDMA in humans.

The mission of “Mind Body Health and Politics” is to enhance health, provoke thought, expand consciousness, and encourage mental health.21. DMT: The Spirit Molecule Now Available on Video

The highly anticipated documentary DMT: The Spirit Molecule was released on October 1, 2011 through Warner Bros. and Gravitas Ventures. The film explores psychedelic ecology, the cultural history of psychedelics, shamanism and ayahuasca, psychedelic research, the effects of psychedelics, spirituality, consciousness, and much more. By remixing current research, thoughts, and theories about psychedelic tools the film helps create a new paradigm for consciousness.

To support the release, the filmmakers created the DMTrmx Project, which utilizes the entire media library (over 100 hours of interviews, 30 hours of footage from the Peruvian Amazon, one hour of VFX, original music, and sound files). Their goal is to enhance the cultural dialogue about psychedelic research by offering the content via a non-commercial Creative Commons license, and making it available for viewing and/or downloading from YouTube and a soon-to-be-launched standalone site (www.DMTrmx.com).

Check out this amazing film, and share it with friends, colleagues, and family members. Both the documentary and the DMTrmx Project aim to have a positive influence on the psychedelic narrative. The film can be seen on iTunes, and a variety of other platforms.

22. Dirty Pictures Documentary Looks at the Genesis of MDMA

A festival hit since its world premiere at the 2010 SXSW Film Festival, Dirty Pictures is a look inside the creation of psychedelics and the mind that made it all possible. Alexander “Sasha” Shulgin is the scientist behind more than 200 psychedelic compounds—including MDMA. Considered to be one of the greatest chemists of the 20th century, Dr. Shulgin’s vast array of discoveries have had a profound impact in the field of psychedelic research, making him a subject of fascination and controversy among fellow scientists and a folk hero to recreational users of psychedelics.

Dirty Pictures uncovers the lifework of Dr. Shulgin and takes viewers inside his Northern California home where he lives with his wife of 40 years and continues to carry out experiments in a makeshift laboratory. Director Étienne Sauret likewise delves into the broader world of psychedelic research—where the fields of chemistry, neuroscience and philosophy intersect—and investigates whether or not this particular field could aid in solving the deepest mysteries of the human mind. For more information on Dirty Pictures, including screeners, final DVDs or interviews with the director and cast, please contact Justin@bgpics.com. Use promotion code “dirty” for a special discount on the DVD.

23.Yarindin Documentary Explores Trauma, Combat, and Psychedelic Healing

Yarindin is a feature-length documentary of combat, love, and the healing journey. It will capture the drama of a band of brothers and sisters who fought together on the fields of battle and now fight to heal together in the fields of the soul, blessed by the beauty of nature and the healing magic of indigenous medicine. Yarindin is the story of a group of veterans ravaged by war who journey to South America for initiation into the indigenous plant medicine of the Amazon. To manifest his vision, ayahuasquero and sound healer Dr. Richard Grossman teamed up with award-winning filmmaker Mark Schwartz. They are currently raising funds for recruiting six to eight traumatized veterans, bringing them to the jungle of Peru for three weeks of ceremonies in late spring of 2012, and documenting the process before, during, and after their journey. The hope is to tell a story so compelling it will touch hearts and minds on a wide scale. Watch the video demo and discover more about this film.

Fundraising News

24. MAPS Celebrates Recent Fundraising Successes

The Multidisciplinary Association for Psychedelic Studies would like to publicly thank all of those who continue to support us in our ongoing work. As psychedelic research expands and more opportunities emerge for medical marijuana, acquiring the financial resources to conduct our work becomes more important than ever. Whether you’ve purchased a book from the store, signed up for a monthly membership, attended a MAPS event, or made a one-time contribution, we—and the countless people who could benefit from these medicines—sincerely thank you.

We especially want to highlight the courage and commitment of the following individuals and foundations:

  • Joseph Kolb for personally contributing $1,000, of which $500 was matched by his employer Xinet for a combined total of $1500.
  • Gerald Gaines and the Compassion First Caregiver Circle of Phoenix, AZ, for a $10,000 grant for our continued work on the protocol review and approval process for our planned study of marijuana for 50 veterans with PTSD.
  • Matt and Kristi Bowden of Stargate International for a $25,000 donation for our upcoming “intern study” of MDMA-assisted psychotherapy for PTSD.
  • Riverstyx Foundation for $50,000 of unrestricted funds for MAPS’ research and educational projects.
  • The Mental Insight Foundation for $60,000 to be used for our ongoing study of MDMA-assisted psychotherapy for PTSD in U.S. veterans.
  • Adam Wiggins for $100,000 of unrestricted funds for MAPS’ research and educational projects.

If you would like to help MAPS develop safe and legal contexts for the therapeutic use of psychedelics and marijuana, please make a donation. Visit our Funding Prioritiespage to learn more about our specific projects and how your gift will be used.New in the MAPS Store

25. The Psychedelic Journey of Marlene Dobkin de Rios: 45 Years with Shamans, Ayahuasqueros, and Ethnobotanists

This book is a look inside almost half a century of pioneering research in the Amazon and Peru by a noted anthropologist of ayahuasca and other psychedelics. Marlene Dobkin de Rios reveals how ayahuasca can be used to successfully treat psychological and emotional disorders through a cross-cultural examination of adolescent drug use and a discussion of the harmful effects of drug tourism in the Amazon. Although late Harvard ethnobotanist Richard Evans Schultes was credited in the early 1950s as being the first to document the use of ayahuasca, other researchers, including Dobkin de Rios, were responsible for furthering his findings and uncovering the curative capabilities of this fascinating compound. The Psychedelic Journey of Marlene Dobkin de Rios presents the accumulated experience of the author’s 45 years of pioneering field studies in the area of psychedelics in Peru and the Amazon. All proceeds help fund MAPS’ psychedelic and medical marijuana research and education.

26. The Psilocybin Solution: The Role of Sacred Mushrooms in the Quest for Meaning

In The Psilocybin Solution, Simon G. Powell traces the history of the psilocybin mushroom and discusses the shamanic visionary effects it can induce. Detailing how psilocybin acts as a profound enhancer of consciousness and reviewing the research performed by MAPS, Johns Hopkins University, and the Heffter Research Institute on psilocybin’s beneficial effects on anxiety in the terminally ill and obsessive-compulsive disorder, Powell examines the neurochemistry, psychology, and spirituality underlying the psilocybin experience, revealing the interface where physical brain and conscious mind meet. All proceeds help fund MAPS’ psychedelic and medical marijuana research and education.

More News

27. Donate an Item to MAPS’ 25th Anniversary Adventure Auction

The Kaleidoscope Vault will take place on December 9 as part of Cartographie Psychedelica [[LINK http://www.maps.org/conferences/25/%5D%5D, our 25th anniversary benefit conference and celebration in the San Francisco Bay Area. We are making an official call for in-kind donations of vacation and timeshare rentals, rare psychedelic memorabilia and collector’s items, gift certificates for local services, and anything else our networks can offer in support. We’re especially seeking experiences, such as travel and adventure activities, that can be auctioned off—especially those related to MAPS’ mission and vision (legal, of course). If you have something that you’d like to offer MAPS to auction off to our supporters, please fill out the auction item donation form. If you have questions, please contact MAPS Store Manager Brian Brown at brown@maps.org.

28. International Ayahuasca Researchers to Meet at Cartographie Psychedelica

Philippe Lucas, M.A., Research Affiliate at the Center for Addictions Research of British Colombia and member of the MAPS Canada board of directors; Brian Anderson, M.D. Candidate at the Stanford University School of Medicine; and Bia Labate, Ph.D., Research Associate at the Institute of Medical Psychology, Heidelberg University, are privileged to organize a meeting and dialogue of international ayahuasca researchers as a adjunct to the upcoming MAPS conference in Oakland. The meeting will take place at the conference site (Oakland Marriott City Center) on Sunday, December 11, from 2:30 – 4:30 PM, and is free but will be exclusive to ayahuasca academics. Participants will be invited to share current projects, successes, and challenges, and to discuss the present and the future of the international ayahuasca research. To sign up for the Ayahuasca Researcher Dialogue, please e-mail Philippe Lucas at philippe.lucas1969@gmail.com to express your interest. Learn more about the full-day ayahuasca research workshop (“Ayahuasca Healing: Medical, Legal, and Cultural Considerations”) taking place on December 12 as part of Cartographie Psychedelica.

29. A Deck of Medicine: Stormrider Calling Cards by Requa Greer Tolbert

Medicine artist Requa Greer Tolbert, with the support of the Women’s Visionary Council, has had her deck of medicine cards reproduced and made available for purchase. The deck was first assembled in 1995 for a Day of the Dead shrine, after years of pioneering research with husband George Greer, M.D., on the therapeutic and spiritual uses of MDMA and ketamine. Having suffered from poor health for a year, the production of the cards have had a profound influence on Mrs. Tolbert’s healing process, as she used the images and poetry they contain to come to a deeper understanding the healing power of these ancient substances, used for millennia in shamanic contexts. Each set of cards includes a book of essays that further address the lore, natural history, and imagery of each card is also available online.

30. MAPS Welcomes New Staff to the Office

We are proud to have Virginia Wright join MAPS as our new Director of Marketing & Development. We also welcome Tess Goodwin as our new Membership & Sales Assistant, as well as our new Receptionist Shannon Clare. Shannon values curiosity, communication, and creating community. After majoring in Cultural Anthropology at the University of California, Santa Cruz, this life-long student is now training in Integral Counseling Psychology at the California Institute for Integral Studies (CIIS). Her favorite activities include backpacking, tango, re-evaluation counseling, and gardening. In addition to her role as Receptionist, Shannon assists the Deputy Director and helps manage the office environment.

http://www.youtube.com/watch?v=fIgSarOjhKw

We have a definite soft spot for Dwayne Polee II (above).  When we heard earlier this week that he was transferring, we were a bit perplexed.  As we opined early on last season, Polee could be a 1 and done talent, only we were thinking NBA, especially after a few highlight reel dunks in the season opener.  As it would turn out, there weren’t too many more of those moments for Polee, who, for the sake of appearances and what well may really be, wants to be closer to home for family reasons, a sick family member, we think.

Polee never really fit in here and that is a terrible shame, because his commitment to the program–the first major talent to sign on–helped St. John’s get the ball rolling in terms of buzz and recruiting, helping them land Norvel Pelle and nearly Remi Barry, other California kids who had a zillion options.  Polee, a symbollic starter for a portion of the season, lost his claim to real minutes early on, after some uneven performances, bad shooting, and terrible decision making.  But he talked the talk, and seemed to have confidence in the program.  One knew as much after an awful Syracuse loss at the Garden, after which Polee spoke to the media about marking the loss and avenging it.

But it couldn’t have been easy for Polee, the only freshman, a guy from the left coast who was much heralded, to join a cliquey St. John’s team, with players who were probably looking at him like competition.  There was a Pennsylvania clique and a JC clique, and there’s the lanky kid from Cali who may not have had anyone to bond with.  Polee probably looked ahead a bit to next season, which was already becoming quite cliquey, and the cliques again did not involve him.  Maurice Harkless, Jakarr Sampson (see his impressive highlights on www.youtube.com above), and D’Angelo Harrison all played on a national all-star team recently, and seemed like they were having a good time together, while tearing it up.  Harkless and Sampson both have a bit of a position clash with Polee, as does Sir Dominic Pointer, who also played in that competition.

Pointer’s high school teammate, Dwight Meickle, has also skipped out on St. John’s, as Steve Lavin announced last month.  Meickle, who is whispered to be only 6’6 and not 6’9, is probably doing the Johnnies a favor.  The quality of recruit St. John’s is now typically in the mix with is well above the talent level of a Dwight Meickle, and we are sure that Lavin and staff will redistribute that scholarship and bring in a bigger talent.  For 2012-2013. 

Right now, as it sits, St. John’s has an extremely thin roster, with only 10 players signed for next season.  One of whom, Nurideen Lindsey, the supposed starting point guard, may not be eligible for the fall.  Of those 10 players, only 1 has NCAA Division I experience, and that’s point guard Malik Stith, who we made fun of all year for his lack of talent.  So we find ourselves questioning St. John’s for next year, though they recently completed a coup by signing power forward God’s Gift Achiuwa.

It was probably never the best thing for the program to give out so many scholarships so quickly.  Not when so many young kids want to wear the jersey.  Was all the pub about the biggest and best class in St. John’s storied history a bad thing?  Not at all.  It was important in getting the program re-established.  And so was Polee, who we are genuinely sad to see go.  He’s a great kid, and we wish him well.

Meickle?  We don’t think he woulld have played much, and we’d just as soon have somebody else.  And from what we hear, with the attention Lavin’s staff is showering on Kyle Anderson, who at 6’8 can play 5 positions, and Ricardo Gathers, we think St. John’s would rather have better players.  They might even get a better player in here to replace Polee, though we were content to sit with him and see his development, and hail him as the first to come.

We still will.  Too bad it will have to be from afar.

Crack (https://crackbillionair.wordpress.com, www.crackbillionair.com)

USA Federation Cup captain Mary Joe Fernandez with tennis power broker husband Tony Godsick (above), who is part of Roger Federer’s management team.

After three days and 8 straight sets of losing tennis, America finally got on the board, taking the first set in doubles at the Porsche Arena in Stuttgart, Germany.  Too bad for our Federation Cup team, our national pride, and the state of American tennis that by then it was too late and obviously too little, as the team of Liziel Huber and Vania King still lost in 3 sets to cap one of the worst weekends in American tennis history.  Needing to win the tie to remain in the World Group of Federation Cup, from which we have never been relegated, Captain Mary Joe Fernandez trotted out an FC squad that did not boast one player of distinction, worthy enough to present a decent challenge to any members of the German squad, including world #156 Sabine Lisicki, who dusted Jersey native Christina McHale in mop up duty yesterday, filling in for Julia Georges, who would have been, at that point, risking her health unnecessarily by continuing to play in a tie that was academic, a glorified exhibition, but one that featured less talent than an actual exhibition.

That’s right.  Playing America is now unnecessary.  The Americans are irrelevant in the women’s game, led by Captain Mary Joe Fernandez, who not so long ago had her contract extended for another two years.  Has the team’s production on the court warranted an extension?  It’s debatable, but we certainly do not think so.  Fernandez, part of the dazed and confused American tennis establishment, is the first captain to ever preside over a relegated team in the history of the Federation Cup.  And we’ll give her little credit for reaching finals in her first two seasons, and losing, but more credit indeed because of the power her husband wields behind the scenes in the game, which in all likelihood, in combination with her profile as an ESPN tennis personality, is what got her the gig.  Because she certainly didn’t win the job on the basis of her success as a player or coach.  In 2010, we especially fault the American squad for losing the championship tie on “hardcourts” in San Diego to Italy.  But in part thanks to Fernandez, California doesn’t have any real hardcourts anymore, and so the ladies played on a track of soft blue foam (the dreaded Plexicushion) that gave the Italians as much of an advantage as the prior year when America could not take one match at Calabria, Italy on outdoor red clay.

How do we get around to blaming Fernandez for everything from California’s putrid tennis courts to the quality of our Fed Cup teams that have failed miserably and continue to do so, to the point that we are out of the world group?  Easily.  She’s the captain.  Not only has she been the captain for 3 years, but before that, she sat at then captain Zina Garrison’s obese elbow for a good year, playing Stan Laurel to Garrison’s Oliver Hardy.  We are tired of it all.  Fernandez obviously endorsed and worked with a Garrison led group that produced zero in terms of titles and developed no meaningful players.  That’s what we mean when call her part of the establishment, for you do not get the captaincy if you do not support the horrid regime that came before you, and the horrid surfaces that big business looks to slap down.

The nonsense about Serena and Venus not playing?  We’ve had enough.  The Williams sisters, when young, led us to our last two Fed Cup titles in 1999 and 2000.  Then they lost interest in the FC, their commitment to it, and the competition.  People want to blame the sisters for that, who had been there and done that.  Part of the whole ‘Let’s rip Venus and Serena for having fashion lines and enjoying the limelight’ craze that swept the nation and still reverberates in some circles.  What people do not get is that the sisters never burnt out on tennis, and continued to play their asses of at majors, in singles and doubles, regardless of any and all outside factors, even when injured.  For players who have won the Federation Cup, or the Davis Cup, there is no legitimate criticism that can exist should they have reasons for skipping the competition.  And while we have criticized Roger Federer in this space for skipping Davis Cup regularly, despite being coached by Swiss DC captain Severin Luthi, Roger obviously has himself a plan to win majors, and Davis Cup runs counter to that plan.

So our body of incompetent tennis minds here in America, with which even we are associated (proud USTA members, LOL–the deals on tennis tickets are too good to pass up!), chooses Garrison, another loser, to guide our squad.  Why?  Because they thought that hiring a black woman would give them a leg up on convincing the Williams sisters to play.  That’s just plain racist.  Frankly, the Williams sisters have a lot more respect for great tennis minds than they do for black women.  Just ask Asha Rolle.  Instead of blaming the Williams sisters for making choices appropriate for their careers, the USTA should have been working a lot harder on developing talented players like Venus, Serena, and Lindsey Davenport–who aside from the Williams sisters, is the last American female to win a title of any sort, as far as we can recall.  And she won it as a ghost, fresh from retirement, further highlighting America’s lack of meaningful young talent.

Yesterday comes news that Venus Williams has withdrawn from Rome and Barcelona, citing her lack of readiness.  There’s no real time table on Serena, and while we know she will return, any projection would be optimistic considering the travails she has endured since cutting her foot.  At least she is up and about (click on the link above to see her and a friend on South Beach recently).  So basically, we are stuck with this piss poor Fed Cup squad and its captain.  Mary Joe Fernandez is not a winner, but is a better politician than Garrison.  Patrick McEnroe, a much worse tennis talent than both, also owes his job to television, politics, and probably a healthy dose of nepotism (his brother lobbied for his appointment, though John John probably wouldn’t have him on his list if you asked him right now, after seeing the state our game go unchanged for years) .  These are the people in whose hands the national tennis program and developmental programs rest in.  Thankfully, Patrick McEnroe has stood aside and Jim Courier, a real winner, has taken on the captaincy of the Davis Cup squad, and is off to a great start, defeating Chile in tough conditions.  As you can tell, we don’t give Patrick McEnroe any credit for squeezing 1 DC title out of a team that boasted a 1 time #1 in Roddick, 2 perennial top 10 guys in Roddick and Blake, and the #1 doubles squad–a huge advantage in team competition.  We should have won more.  But at least McEnroe, roundly criticized, even by big brother John, had the sense to pick fast tracks to play on as the host nation that are advantageous to Americans and our style of tennis.

Fernandez gets no credit.  She’s been around this team for 4 years and we’ve seen all we need to see of Oudin, McHale, Vandeweghe, and the like.  People want to shower MJF with praise for spotting these players, but these players would go unnoticed anywhere else, with good reason.  They have no talent.  They are grinders who can not even play on clay.  Pop gun players who can’t serve and have no true tennis talent.  What is the population of Germany?  How is it that our top player can’t take a set from any decent German woman?  How is it that none of our players could even make the German squad, who was also competing to avoid relegation?  This is not a Steffi Graf in her prime led German team.

McHale, for a nice run she made at Indian Wells last month, will get some buzz, but if she is the young face of our game, we need a makeover.  Fast.  Forget Venus and Serena.  Act like they don’t exist.  Oudin?  Since that summer where she played way over her head, she hasn’t existed.  We need new blood, new ideas, new coaches, new courts…and a new captain.  Probably the best young American, Alison Riske, who separates herself from her poor pusher peers with her big serve, is not a product of the USTA, but rather, a kid who came up playing in the Pennsylvania high school system.  Exactly John McEnroe’s point when he denigrates the work that his brother is doing, the state of the American game, and the homogenization of the American game which is now one dimensional baseline half tennis.

Since Fernandez won’t be fired, especially with a new pact in hand, here’s some advice for her: pick Decoturf, a surface which will speed up her players’ 80 mph 1st serves and slow groundstrokes.  It’s the national surface for a reason, and Americans play better on it than any other nation does.  And feature the girls with actual potential, like Lauren Davis, Riske, and Sloane Stephens.  McHale and Oudin haven’t exactly done wonders for the nation.  Riske at least has a bigger game and a bigger frame with which to cover the net, and Davis and Stephens have expectations in place, and are used to dealing with expectations, as they are the only true budding pros we have of note.  We’d also probably put a veteran doubles player like Craybas or Mattek-Sands (when healthy) with Huber and work on locking up at least 1 match in every tie.

For future reference, the captain does not need to be a woman, and if it is, it needs to be a woman with a real winner’s pedigree, which means, probably not an American.  Richard Williams has produced the two greatest American women of our time.  He should be on the short list.  As should Monica Seles, who is a fixture in the game and who actually commands the respect of young players based on her merits.

Crack (https://crackbillionair.wordpress.com, http://www.crackbillionair.com)

Artem Anisimov (blue) pays the price to make a play against the hated New Jersey Devils (above).

https://crackbillionair.wordpress.com/2010/11/18/rangers-toughen-up/

Rangers’ coach John Tortorella recently announced that captain Chris Drury would return to the lineup tonight in Pittsburgh.  On its own, the declaration did nothing to stir our confidence.  Drury is a hard working guy, a stand up guy, but let’s be frank–he hasn’t lived up to his $35M contract and the last really clutch goal he scored was against, not for, the Rangers.  It was the way Torts said it that was such music to my ears, the song of angels to long time fans of the team.  The coach said Drury will play but that “no kids are coming out.”  Tortorella went on to say that it would be veterans who lose ice time and that a veteran would be a healthy a scratch, and that it was too bad for them.  “He’s the captain,” Tortorella would say.  “Everybody’s gotta sacrafice.”

On Sunday night the New York Rangers played perhaps their best game against a quality opponent in years, shutting out the Capitals 7-0.  It was the most lopsided shutout victory the team has had since 1970 (and my wife deleted it off the tivo before I saw the 4 goal 2nd period–an “important” American Idol will be deleted in retaliation).  The Rangers have a quality team because of the kids they’ve developed and refused to trade.  And a lot of them are kids no more.  Anisimov, the 6’4, 220 lbs. center iceman, may have slumped a bit as all players do, but he’s a leading scorer and a cog on the team’s best line, which flat out beats opposing units up physically on the wall and with its relentless cycle.  The line is so good that it allowed the Rangers to withstand almost a month without world class forward Marian Gaborik, and so good that on most nights since returning, Gabby has been a compliment and not that absolute focal point he’s been on every team he has played on in his life, including the Slovak national team that’s chock full of talent up front.

Defensemen Marc Staal and Dan Girardi who had us pulling our hair out as recently as all of last year, have grown into cornerstones of the team, and now even look polished offensively.  Imposing rookie defenseman Michael Sauer won the Rangers a game last week in Ottawa with a well placed point shot in the clutch.  Team USA stalwart Ryan Callahan, perennially our extra effort award winner, does everything for this team but drive the Zambonie, and is loathe to miss a shift despite being a league leader in both hits and blocked shots.  We feel that Drury is keeping the captain’s C warm for him.

Derek Stepan has been a rookie sensation and now, playing consistently with Gaborik, expect him to flourish even more.  The core of youth has played so well that it can carry a guy like Michael Del Zotto, a sophomore defenseman who looks lost out there and who’s struggling very badly.  Then there’s team scoring leader and maybe the manliest man of the bunch, emerging star power forward Brandon Dubinsky, recently seen screaming at and giving the look of death to the Ottawa bench, last seen, kicking Alexander Ovechkin’s ass all over the ice on Sunday.  You think Dubinsky will be fired up tonight to face his best girlfriend Cindy Crosby, who cheaply and classlessly gave Ryan Callahanthe slew foot in the 2 team’s last meeting?

Whatever happens tonight, New York is bringing the right mix of size, speed, talent, toughness, and meanness to the party, even in the absence of behemoth enforcer Derek Boogard, who is still out with a shoulder problem.  The Rangers are seeking to win their second straight in Pittsburgh and to get a win over a Penguin team that last night had a 12 game win streak snapped by the Flyers.

LET’S GO RANGERS!!!!!

Crack (https://crackbillionair.wordpress.com, www.crackbillionair.com)

ESPN reported earlier today that Ben Roethlisberger came out against the NFL’s announcement this week that hits to the head would be punished to the letter of the rules, and will include big fines as well as suspensions.  Supposedly Big Bad Ben and backup Byron Leftwich had a meeting of the minds and came up with the theory that they’d rather have the concussion than a more serious injury somewhere else.

But we know the real reason, right?  Because Roethlisberger doesn’t use his brain anyway.  He thinks with his dick.

https://crackbillionair.wordpress.com/2010/06/10/roethlisberger-accuser-it-was-kinda-like-they-had-it-planned/

https://crackbillionair.wordpress.com/2010/04/18/roethlisberger-down-to-fuck/

https://crackbillionair.wordpress.com/2010/04/19/roethlisberger-played-unwanted-penis-game-with-other-georgia-woman/

https://crackbillionair.wordpress.com/2010/04/22/roethlisberger-could-have-been-prosecuted-for-supplying-alcohol-to-a-minor/

https://crackbillionair.wordpress.com/2010/04/25/roethlisberger-reputation-takes-more-hits/

https://crackbillionair.wordpress.com/2010/08/01/big-ben-pittsburghs-media-darlinghero-of-sexual-misconduct/

Crack (https://crackbillionair.wordpress.com, www.crackbillionair.com)

Philadelphia standout point guard prospect Nurideen Lindsey (above).

Lindsey, the former Philly prep star now at Redlands CC in Oklahoma, accepted a scholarship offer from the Red Storm Tuesday. The other finalist for his services was Auburn, though Kentucky, South Florida, Oklahoma State and LSU all were involved too.

“The thing that made St. John’s right for him was the relationship and comfort he has with the coaching staff,” said Redland coach Yaphett King. “They made it clear with their action how much he mattered to them. Every opportunity they could see him, they were there.”

In 2008 the 6-3 Lindsay played at Philadelphia‘s Overbrook High and committed to LaSalle, where current Storm assistant Tony Chiles was on staff at the time. That year he averaged 35.8 points in league play, the sixth highest ever with Chamberlain holding two of the top five spots. Chamberlain also attended Overbrook.

 http://www.nydailynews.com/sports/college/2010/10/19/2010-10-19_nurideen_lindsey_basketball_prospect_from_philadelphias_overbrook_high_picks_red.html?r=sports#ixzz12wRWYAYi

Lindsey, sadly, saw two of his brothers murdered in Philadelphia, which swayed him to leave his hometown for Redlands CC in Oklahoma.  The 6’3 lead guard was one of the best high school scorers in Pennsylvania history, and had originally decided to attend Lasalle.  It was current St. John’s assistant Tony Chiles, then at Lasalle, who was instrumental in signing Lindsey, then and now, successfully re-recruiting one of the nation’s most talented guard prospects to St. John’s. 

St. John’s also secured a commitment from Detroit area small forward and defensive “stopper” Dominick Pointer, who considers himself a lockdown forward.  With the Pointer and Lindsay signings, new St. John’s coach Steve Lavin can boast that the program has gone into 5 high school basketball hotbeds and landed a stud from each: Dwayne Polee Jr (Los Angeles), Maurice Harkless (NYC), D’Angelo Harrison (Houston), Pointer (Detroit), and Lindsay (Phily).  Lavin also received a commitment from Akron, Ohio HS star Jakarr Sampson.

Though we expected St. John’s to make a big splash at point guard, we were thinking more along the lines of a traditional distributor at the lead guard position.  Since St. John’s still has 5 scholarships to give in the 2011 class, we are hoping they can still sign a pass first point.  But for a team that has struggled to score for almost 15 years, it’s refreshing to have 2 respected scorers in the backcourt, as well as Polee, who we think will fill it up in the front court.  As for style of play, we know special advisor Gene Keady always favored a methodical approach, and that he preaches patience and taking care of the ball. 

It should be interesting to see how Lavin and Keady find the right mix of styles to suit the stable of thoroughbreds Lavin has brought in, which is essentially made up of two scoring guards, as Lindsay is a shoot first player, and 4 small forwards.  Expect Lavin to turn his attention to signing at least a few impact big men with the remaining 5 scholarships he has available.

We’re actually more excited about St. John’s than the Knicks right now.  Feels like old times.

https://crackbillionair.wordpress.com/2010/10/16/lavin-quickly-restores-credibility-to-st-johns/

Crack (https://crackbillionair.wordpress.com, www.crackbillionair.com

Tablet Photo Tablet NameTablet Name is the street name that was submitted with the tablet (or the common street-name for an imprint if no name is submitted with a tablet). The individual tablet page may also give alternative names based on similar tablets that have been submitted in the past or information collected by the source organization. Active ContentsActive Contentsis a list of substances detected by the lab. Date PublishedDate Published is in most cases within two weeks of the date that the tablet was received by the lab (MAPS and other non-Ecstasydata results not included). Date TestedDate Tested the approximate date when the sample was tested by the lab. Location Tablet SizeTablets are weighed and measured with tablet diameter and height being displayed in millimeters (mm) and weight displayed in milligrams (mg). This is the full weight of the tablet, including all binders and fillers and is not the mass of the detected substances. Data SourceMost of the data on EcstasyData.org is for tablets submitted by the public with lab testing organized by the EcstasyData project. Various organizations have also contributed data to EcstasyData.org. Links are provided to contributing organizations’ websites as well as to information describing the organization and their involvement with the EcstasyData.org project.
Substance Ratio /
AmountsRatio/Amounts are, in most cases, the relative amount of the detected substances. When a single substance is detected, the ratio will always be “1”. When a mass is given, that is the actual amount of drug in the full submitted sample.
1929 G Lady
  • MDMA
  • 1
Jul 21, 2010 Jul 21, 2010 Deer Park, NY 382 mg, 9.2 x 4.9 EcstasyData.org
1930 white puma
  • MDMA
  • 1
Jul 21, 2010 Jul 21, 2010 Carthage, NY 176 mg, 7.2 x 4.0 EcstasyData.org
1931 White Diamond
  • TFMPP
  • BZP
  • 3
  • 2
Jul 21, 2010 Jul 21, 2010 Carthage, NY 282 mg, 8.6 x 4.2 EcstasyData.org
1932 Pink Monkey
  • TFMPP
  • Pseudo/Ephedrine
  • Caffeine
  • 3
  • 2
  • 1
Jul 21, 2010 Jul 21, 2010 Carthage, NY 329 mg, 8.1 x 6.0 EcstasyData.org
1933 G Lady
  • MDMA
  • 1
Jul 21, 2010 Jul 21, 2010 New York, NY 393 mg, 9.2 x 4.8 EcstasyData.org
1934 Red Diamond
  • MDMA
  • 1
Jul 21, 2010 Jul 21, 2010 Los Angeles, CA 317 mg, 9.3 x 5.1 EcstasyData.org
1935 Methylone
  • Methylone
  • 1
Jul 21, 2010 Jul 21, 2010 Alief, TX EcstasyData.org
1936 Green AK-47
  • Caffeine
  • Unidentified
  • 2
  • 1
Jul 21, 2010 Jul 21, 2010 High Point, NC 291 mg, 8.0 x 5.7 EcstasyData.org
1938 Superman
  • TFMPP
  • BZP
  • MDMA
  • 4
  • 2
  • 1
Jul 21, 2010 Jul 21, 2010 St. Paul, MN 298 mg, 7.1 x 4.9 EcstasyData.org
1939 triangle
  • None Detected
Jul 22, 2010 Jul 01, 2010 New York, NY 264 mg, 8.1 x 5.3 EcstasyData.org
1940 Homer Simpson
  • TFMPP
  • BZP
  • 20
  • 1
Jul 22, 2010 Jul 01, 2010 Miami, FL 268 mg, – x – EcstasyData.org
1941 Puma
  • MDMA
  • Caffeine
  • 20
  • 1
Jul 22, 2010 Jul 01, 2010 Los Angeles, CA 355 mg, 9.3 x 5.0 EcstasyData.org
1942 abby road
  • MDMA
  • Procaine
  • 2
  • 1
Jul 22, 2010 Jul 01, 2010 San Francisco, CA EcstasyData.org
1943 Starlight
  • MDMA
  • 1
Jul 22, 2010 Jul 01, 2010 San Francisco, CA EcstasyData.org
1944 fleur de lis
  • TFMPP
  • BZP
  • 5
  • 1
Jul 22, 2010 Jul 01, 2010 San Francisco, CA 291 mg, 8.1 x 4.9 EcstasyData.org
1945 wholly molly
  • MDMA
  • Methylsulfonylmethane
  • 25
  • 1
Jul 22, 2010 Jul 01, 2010 Cabin John, MD EcstasyData.org
1946 triple crown
  • MDMA
  • 1
Jul 22, 2010 Jul 01, 2010 Orlando, FL 296 mg, 8.1 x 5.3 EcstasyData.org
1927 blue dolphin
  • MDMA
  • 1
Jun 17, 2010 Jun 17, 2010 Boston, MA 319 mg, 8.1 x 5.8 EcstasyData.org
1928 smiley
  • mCPP
  • 1
Jun 17, 2010 Jun 17, 2010 Copenhagen, Denmark 221 mg, 8.1 x 3.2 EcstasyData.org
1923 PL
  • None Detected
Jun 16, 2010 Jun 16, 2010 Cohasset, MA 221 mg, 8.1 x 4.3 EcstasyData.org
1924 blue bomb
  • MDMA
  • Caffeine
  • 5
  • 1
Jun 16, 2010 Jun 16, 2010 Los Angeles, CA 292 mg, 8.1 x 6.3 EcstasyData.org
1925 internet explorer
  • MDMA
  • Caffeine
  • 5
  • 1
Jun 17, 2010 Jun 16, 2010 Los Angeles, CA 299 mg, 8.2 x 6.0 EcstasyData.org

https://dancesafe.org/content/story/july-ecstasydata-review-crackbillionair

https://crackbillionair.wordpress.com/2010/08/02/crackbillionair-teams-with-dancesafe-for-the-good-of-the-scene/

www.dancesafe.org has published our latest piece on www.ecstasydata.org’s lab results, as promised.  Check it.

Be Smart,

Crackbillionair (https://crackbillionair.wordpress.com, www.crackbillionair.com)

Next Page »